Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 1, 2026Therapeutic Advances in HematologyOpen Access

Real-world efficacy and safety of the carfilzomib–pomalidomide–dexamethasone regimen in patients with relapsed/refractory multiple myeloma: A multicenter retrospective study

View Full Paper
Ask AI
Bookmark
Share

Authors

HFHuishou FanXFXiangyan FengRWRongxia Wei

Discussion

Loading...

Member takes

Overview

Multicenter retrospective study reveals favorable efficacy and manageable toxicity of KPd in relapsed/refractory multiple myeloma, indicating greater survival benefits in early-line treatment.

Key Points

  • To evaluate the real-world clinical efficacy and safety of the carfilzomib-pomalidomide-dexamethasone (KPd) regimen across different treatment lines in relapsed or refractory multiple myeloma.
  • Retrospective multicenter study across four centers in China including N=82 patients with relapsed/refractory multiple myeloma who received at least one cycle of KPd.
  • Patients were stratified by lines of treatment (LOT) at initiation: second-line (2L, n=39), third-line (3L, n=26), and fourth-line or beyond (4L+, n=17), with a median follow-up of 10.8 months.
  • Overall response rate across 72 evaluable patients was 69.4%, with line-specific rates of 79.4% in 2L, 73.9% in 3L, and 40.0% in 4L+.
  • Median progression-free survival (mPFS) was 22.5 months overall (not reached [NR] in 2L, 22.5 months in 3L, and 10.1 months in 4L+; P=0.178); median overall survival (mOS) was NR overall (NR in 2L, NR in 3L, and 11.6 months in 4L+; P=0.019).
  • Multivariable analysis identified LOT ≥4 (HR=2.791, 95% CI: 1.086–7.177, P<0.05) and elevated lactate dehydrogenase (HR=3.489, 95% CI: 1.557–7.823, P<0.05) as independent predictors of shorter PFS, while grade ≥3 adverse events occurred in 12.8% (2L), 50.0% (3L), and 47.1% (4L+) of patients.

Cite This Study

Fan et al. (2026) studied this question.

synapsesocial.com/papers/6a93a153213a779dfe7208a7https://doi.org/10.1177/20406207261481202
View Full Paper
Ask AI
Bookmark
Share